Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A
C. Pilette (Bruxelles, Belgium), G. Canonica (Milan, Italy), R. Chaudhuri (Glasgow, United Kingdom), F. Lee (Atlanta, GA, United States of America), J. Lee (Toronto, ON, Canada), C. Almonacid Sanchez (Madrid, Spain), R. Alfonso-Cristancho (Collegeville, PA, United States of America), R. Jakes (London , United Kingdom), A. Maxwell (Stevenage, United Kingdom), R. Price (Stevenage, United Kingdom), P. Howarth (Brentford, United Kingdom)
Source: Virtual Congress 2021 – Advances in asthma treatment
Session: Advances in asthma treatment
Session type: E-poster
Number: 3539
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Pilette (Bruxelles, Belgium), G. Canonica (Milan, Italy), R. Chaudhuri (Glasgow, United Kingdom), F. Lee (Atlanta, GA, United States of America), J. Lee (Toronto, ON, Canada), C. Almonacid Sanchez (Madrid, Spain), R. Alfonso-Cristancho (Collegeville, PA, United States of America), R. Jakes (London , United Kingdom), A. Maxwell (Stevenage, United Kingdom), R. Price (Stevenage, United Kingdom), P. Howarth (Brentford, United Kingdom). Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A. 3539
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: